Industry News: New Developments for Acute Myeloid Leukaemia

The FDA has recently announced its approval of the very first treatment for certain types of poor-prognosis acute myeloid leukaemia (AML for short). AML is a frighteningly rapidly progressing cancer which forms in the bone marrow and as a result increases the number of white blood cells in the bloodstream.

The National Cancer Institute at the National Institutes of Health estimates that approximately 21,380 people will be diagnosed with AML this year; approximately 10,590 patients with AML will die of the disease in 2017. A terrifying high number of people only living for a couple of months following their diagnosis.

This new drug development far from promises to cure this rapid deterioration in patient health, more tries to slow AML and offer the patient an improved quality of life following diagnosis. The drug names Vyxeos was recently studied in 309 patients who had just received their diagnosis. The trial measured how long patients lived from the date they started the trial. Patients who received Vyxeos lived longer than patients who received separate treatments of daunorubicin and cytarabine. A median overall survival 9.56 months vs. 5.95 months, which is not far off doubling life expectancy following diagnosis.

This new drug approval far from cure this shockingly rapid condition but the FDA are hopeful it may be able to be developed further in the future perhaps.

Read the full article: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm569883.htm